Unleashing the power of mRNA
TriLink is determined to deliver innovative nucleic acid tools and services to help you bring transformative nucleic acid therapies from research to patients.
Where are you in your mRNA development?
Accelerate your drug research and discovery timelines
Start your mRNA development with the right foundation - we provide innovative technologies and support to assist your R&D development process.
- Catalog mRNA
- CleanCap® technology
- Catalog and customer NTPs
- Discovery mRNA synthesis
The promise of mRNA made real
Advance your therapeutic candidates to the clinic
The path to the clinical phase can be long and complex. TriLink provides comprehensive support and quality resources to bring your candidate therapeutic one step closer to clinic.
- mRNA synthesis and optimization services
- Plasmid DNA-to-mRNA pathway
- Analytical methods development services
- CleanCap® technology
- NTPs
The promise of mRNA made real
Scale your process to meet clinical trial requirements
The race to begin clinical trials can come quickly, and you need to make sure you have a partner capability of scaling with you. TriLink leverages a complete portfolio of CDMO services, include GMP-scale manufacturing, and a comprehensive catalog of GMP-reagents to help meet accelerated timelines.
Learn more about support for clinical development
The promise of mRNA made real
Your preferred partner to help meet commercial demands
TriLink's GMP-grade reagents and technologies have been used in global commercial manufacturing programs, including a leading COVID-19 vaccine.
- GMP-grade CleanCap® technology
- GMP-grade Modified uridine nucleotides
The promise of mRNA made real
Determined to deliver effective mRNA capping solutions
An essential part of any mRNA compound is the 5’ cap structure, which is critical to the stability, expression, and immunogenicity of an mRNA. We revolutionized mRNA capping strategies with our one-pot CleanCap® capping solutions generating the optimal Cap1 structure with more than 95% efficiency.
Learn moreScalable processes and manufacturing
Maintaining scalability allows your project to keep to the timeline, absorb unexpected surges in demand, and remain aligned with your clinical research goals. Our 118,000 sq ft facility contains multiple specialized manufacturing suites and support labs, ensuring success across a wide variety of scales.
Learn moreAnalytical support
We have developed extensive in-house capabilities in method development and analytical testing to ensure a high-quality manufacturing process. We work with you to ensure effective method development to meet your objectives. Analytical services available for CleanCap® capping technologies include active moiety quantification, identification, purity, as well as safety and contaminating nucleases for GMP grade products.
Learn more- Summary - Intro
- Equipment/Scale
- Analytics
Custom NTPs
We synthesize ultrapure novel nucleotides to meet your specific platform needs. Our expert chemistry team offers custom synthesis of complex modified nucleotides and amidites from the discovery phase to scale up into multi-kilogram quantities. Our experts can guide you to the best solution for your platform needs and provide flexibility to accommodate the stage of your project/program.
Learn more- Custom NTPs (Custom Chemistry)
Go further with mRNA synthesis services
TriLink’s proprietary mRNA synthesis capabilities include CleanScript™ in vitro transcription method optimized to decrease dsRNA, scales ranging from milligram to multi-gram, and lengths ranging from a few hundred nucleotides to over 14 kilobases.
Learn moreDiscovery mRNA manufacturing
Analytics for mRNA characterization
TriLink’s analytical testing and QC assay capabilities to support mRNA programs include identity, characterization, impurity, and safety testing. Our expert analytical services team also offers construct-specific assays and method development.
Learn more- Go further with mRNA synthesis services
- Discovery mRNA manufacturing
- Analytics for mRNA characterization
Oligo synthesis
TriLink has been an industry leader in synthesizing high quality oligonucleotides for research, diagnostics, therapeutics, and OEM for more than 20 years. We offer a wide selection of DNA, RNA, modified, and specialty oligonucleotides in scales up to multiple grams.
Learn moreCustom RNA oligos
TriLink specializes in synthesizing challenging constructs, such as highly modified gRNA, siRNA, microRNA and aptamers, as well as scaling up to mid-scale quantities, 50 mg to multiple grams. For long RNAs with 100+ bases please see the TriLink mRNA custom synthesis long RNA synthesis by in vitro transcription service.
Learn moreCustom DNA oligos
TriLink offers premier quality DNA oligonucleotides in both standard and complicated sequences and modifications, at the scale and purity you need.
Our extensive options for modifications are unparalleled in the industry and include backbone modifications, dye labels and quenchers, modified and inverted bases, linkers and spacers, 5' terminal caps, biotin and other conjugation, dimers and trimers, and more.
Learn moreAnalytics for oligo synthesis
TriLink has optimized the synthesis and purification of RNA and DNA oligos. Every oligonucleotide manufactured at TriLink undergoes quality control analysis by PAGE, HPLC, and/or MS. Further service options are available including additional purifications and analyses, annealing, aliquoting, and formulation.
Learn more- Summary - Intro
- Equipment/Scale
- Equipment/Scale
- Analytics
Get to market faster with an effective mRNA capping strategy
TriLink has revolutionized mRNA capping strategies with its one-pot CleanCap® capping solutions generating the optimal Cap1 structure with more than 95% efficiency.
Learn moreScalable processes and manufacturing
Maintaining scalability allows your project to keep to the timeline, absorb unexpected surges in demand, and remain aligned with your clinical research goals. Our 118,000 sq ft facility contains multiple specialized manufacturing suites and support labs, ensuring success across a wide variety of scales.
Learn moreFind the right analog for your application
TriLink BioTechnologies continues to innovate its growing offering of cap analogs to help meet a variety of applications including CleanCap technology.
Learn moreAnalytical support
TriLink has developed extensive in-house capabilities in method development and analytical testing to ensure a high-quality manufacturing process. We work with you to ensure effective method development to meet your objectives at each stage of product development. Analytical services available for CleanCap technologies include: active moiety quantification, purity, and identification.
Learn more- Summary - Intro
- Equipment/Scale
- Process Dev/Innovation
- Analytics
TriLink offers a wide selection of modified nucleoside triphosphates (NTPs) to suit your application needs. We have more than 150 modified NTPs in our ready-to-make portfolio, including aminoallyl, biotin, 2' fluoro, and dye-labeled nucleotides. In addition, we offer specialty modified nucleotides such as 5'-3' bisphosphates, a series of monophosphates, alpha-thiol NTPs, and cap analogs.
Learn moreScale swiftly from the bench to the clinic
Our modified NTP portfolio provides peace of mind when scaling from the bench to the clinic. We operate an ISO 9001:2015 facility, ensuring your mRNA production materials meet reported requirements for identity, purity, and safety. Our stringent quality systems and dedicated team of experts ensure consistency in the product, process, and documentation.
Learn moreThe first-ever GMP-grade NTPs
As one of the first manufacturers of N1-methylpseudouridine-5’-triphosphate, TriLink provides some of the best NTPs on the market—including the first GMP-grade chemically synthesized NTPs available.
Learn more- Summary - Intro
- Equipment/Scale
- Process Dev/Innovation
GMP mRNA manufacturing
Partner with a leading mRNA innovator with 25+ years of proven manufacturing performance. Leverage TriLink's scale up, GMP mRNA manufacturing expertise, and in-house analytical services and method development for mRNA characterization.
Learn moreGMP capabilities
TriLink is expanding its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.
Learn morePlasmid DNA-to-mRNA pathway
To shorten timelines and simplify supply chains, integrate phase-appropriate, high-quality plasmid DNA templates into your mRNA manufacturing process with TriLink’s plasmid DNA-to-mRNA pathway, designed and optimized to support clinical mRNA therapeutic and vaccine programs.
Learn moreProcess development and scale-up expertise
At TriLink, each mRNA drug substance manufacturing program is supported by a team of mRNA manufacturing experts, providing guidance in program management, process development, scale-up, analytical services, quality, and manufacturing.
Learn moreAnalytical services for mRNA drug substance
Comprehensive analytical testing and quality control (QC) assays are performed to ensure the purity and integrity of the mRNA drug substance. Our in-house analytics team has extensive experience developing, qualifying, validating, and performing analytical methods.
Learn more- Summary - Intro
- Equipment/Scale
- Plasmid Manufacturing
- Process Dev/Innovation
- Analytics
Determine your future with TriLink
For over 25 years, TriLink has led the way in all things mRNA.
Join us in making history, as we help our partners achieve remarkable advances in the field of medicine.
